Inhibitors of Transporters or Uptake of Monoaminergic Neurotransmitters


Technology Description


This technology is a simple and efficient way for synthesizing Synosutine, a drug to be potentially used to treat depression and neuropathic pain.


Features & Benefits


  • Much more efficient and quicker synthesis pathway than that for Cymbalta
  • More balanced inhibition of serotonin and norepinephrine transporters makes Synosutine potentially a better treatment for neuropathic pain
  • In vitro binding and in vivo microdialysis data available




  • Treatment for depression and neuropathic pain


Background of Invention


One form of medical treatment for depression and neuropathic pain features a dual inhibitor called Cymbalta. This drug is manufactured and marketed by Eli Lilly. Researchers at Oregon State University have discovered a very efficient way of synthesizing Synosutine, which is comparable to Cymbalta in limited in vitro and in vivo assay. This drug could have powerful implications for treatment of depression and neuropathic pain.


Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Inhibitor(S) Of Transporters Or Uptake Of Monoaminergic Neurotransmitters Utility United States 13/355,371 8772330 1/20/2012 7/8/2014 7/28/2032
Tech ID:
Joe Christison
Assistant Director, IP & Licensing
Oregon State University
James White
David Chan
David Wong
Rajan Juniku
Jongtae Yang
© 2024. All Rights Reserved. Powered by Inteum